{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:29:43Z","timestamp":1777303783177,"version":"3.51.4"},"reference-count":29,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Antitumor necrosis factor-\u03b1 (anti-TNF-\u03b1) therapy is the most prescribed biologic agent therapy in rheumatology and gastroenterology. However, a number of serious side effects have been reported with these drugs. Only a handful of cases of new-onset inflammatory bowel disease (IBD), mostly in children diagnosed with juvenile idiopathic arthritis (JIA), have been reported during anti-TNF-\u03b1 therapy. We present 3 cases of adult IBD following anti-TNF-\u03b1 therapy and a literature review on this topic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We searched PubMed MESH for all relevant terms, papers were reviewed, and patient-specific data were extracted. Relevant clinical data were calculated and presented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>The PubMed search resulted in 137 articles, of which 11 articles and 4 cited publications were included in our analysis. We found 53 cases of IBD after anti-TNF-\u03b1 therapy reported in the literature; most of them were case series collected retrospectively from national databases or studies. Almost all the patients developed IBD after the introduction of etanercept (ETN); 2 patients with rheumatoid arthritis were also included. The average age at IBD onset was 17.3 years and the average time from ETN introduction to IBD onset was 27 months (\u00b1 24). Gastrointestinal symptoms have been reported as improving or subsiding in most of the patients after discontinuing ETN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Although this manifestation is not common, it should be taken into consideration as an adverse effect of ETN. Rheumatologists, and in particular rheumatologists treating adult patients, should be aware of this possible complication. Further investigation about the pathogenic process underlying this phenomenon is warranted.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.160952","type":"journal-article","created":{"date-parts":[[2017,4,16]],"date-time":"2017-04-16T00:10:12Z","timestamp":1492301412000},"page":"1088-1095","source":"Crossref","is-referenced-by-count":20,"title":["Antitumor Necrosis Factor-\u03b1 Therapy Associated with Inflammatory Bowel Disease: Three Cases and a Systematic Literature Review"],"prefix":"10.3899","volume":"44","author":[{"given":"Amir","family":"Bieber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdallah","family":"Fawaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Novofastovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reuven","family":"Mader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2017,4,15]]},"reference":[{"key":"2018112909371011000_44.7.1088.1","unstructured":"Taylor PC . Tumor necrosis factor - blocking therapies. In: Hochberg MC Silman AJ Smolen JS Weinblatt ME Weisman MH , editors. Rheumatology, 2-volume set, 6th ed. New York: Elsevier; 2015:492\u2013500."},{"key":"2018112909371011000_44.7.1088.2","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909371011000_44.7.1088.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100809"},{"key":"2018112909371011000_44.7.1088.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140472"},{"key":"2018112909371011000_44.7.1088.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.069484"},{"key":"2018112909371011000_44.7.1088.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq136"},{"key":"2018112909371011000_44.7.1088.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2011.10.001"},{"key":"2018112909371011000_44.7.1088.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes019"},{"key":"2018112909371011000_44.7.1088.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-0991-7"},{"key":"2018112909371011000_44.7.1088.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.10885"},{"key":"2018112909371011000_44.7.1088.11","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200408000-00016"},{"key":"2018112909371011000_44.7.1088.12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000381637","article-title":"New onset, aggravation and recurrence of Crohn\u2019s disease upon treatment with three different tumor necrosis factor inhibitors","volume":"9","author":"Zeitz","year":"2015","journal-title":"Case Rep Gastroenterol"},{"key":"2018112909371011000_44.7.1088.13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/03009742.2010.499878","article-title":"Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab","volume":"40","author":"Tarkiainen","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"2018112909371011000_44.7.1088.14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00384-011-1250-4","article-title":"Pancolitis during etanercept treatment of rheumatoid arthritis relapsing on the administration of further two TNF-alpha inhibitors","volume":"27","author":"Actis","year":"2012","journal-title":"Int J Colorectal Dis"},{"key":"2018112909371011000_44.7.1088.15","first-page":"31","article-title":"[Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis]","volume":"58","author":"Pontikaki","year":"2006","journal-title":"Reumatismo"},{"key":"2018112909371011000_44.7.1088.16","first-page":"342","article-title":"Emergence of Crohn\u2019s disease in juvenile idiopathic arthritis during treatment with etanercept: a causal link or a mere coincidence?","volume":"19","author":"Oikonomou","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"key":"2018112909371011000_44.7.1088.17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1055\/s-0033-1355391","article-title":"Crohn\u2019s disease in a patient with juvenile idiopathic arthritis after starting etanercept therapy - causal link or only temporal coincidence?","volume":"225","author":"Flemming","year":"2013","journal-title":"Klin Padiatr"},{"key":"2018112909371011000_44.7.1088.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-3133-9"},{"key":"2018112909371011000_44.7.1088.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.02.021"},{"key":"2018112909371011000_44.7.1088.20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2147\/PPA.S33109","article-title":"Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis","volume":"7","author":"Senabre-Gallego","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"2018112909371011000_44.7.1088.21","first-page":"619","article-title":"[Onset of Crohn\u2019s disease induced by etanercept therapy: a case report]","volume":"67","author":"Mrabet","year":"2012","journal-title":"Rev Med Liege"},{"key":"2018112909371011000_44.7.1088.22","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.117"},{"key":"2018112909371011000_44.7.1088.23","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"2018112909371011000_44.7.1088.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.12.1440"},{"key":"2018112909371011000_44.7.1088.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00382-2"},{"key":"2018112909371011000_44.7.1088.26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091233"},{"key":"2018112909371011000_44.7.1088.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.2.133"},{"key":"2018112909371011000_44.7.1088.28","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90202-V"},{"key":"2018112909371011000_44.7.1088.29","doi-asserted-by":"publisher","DOI":"10.1016\/0899-7071(95)00046-S"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.160952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T19:16:03Z","timestamp":1543518963000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.160952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,15]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,1]]},"published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.3899\/jrheum.160952"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.160952","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,15]]}}}